J&J, Alligator strike immuno-oncology MAb deal worth up to $700m
Johnson & Johnson's Janssen Biotech, Inc. has snapped up Alligator Bioscience's immuno-oncology MAb, ADC-1013, in a deal potentially worth $700m to the small Swedish drug developer.
Johnson & Johnson's Janssen Biotech, Inc. has snapped up Alligator Bioscience's immuno-oncology MAb, ADC-1013, in a deal potentially worth $700m to the small Swedish drug developer.